Celltrion

Dear Valued Shareholders,

On September 20 (local time), Celltrion entered into an agreement with global pharmaceutical company Eli Lilly to acquire its U.S. manufacturing facility. To finalize the acquisition, approvals for “business combination” from both the U.S. and Irish governments are required, and we are proceeding with these procedures without delay.

As part of this process, on October 31 (local time), Celltrion obtained approval for the business combination related to the acquisition of Eli Lilly’s U.S. manufacturing facility from Ireland’s Competition and Consumer Protection Commission (CCPC). We would like to take this opportunity to promptly share the update with our shareholders.

As both Celltrion and the target facility record a certain level of sales in Ireland, obtaining merger clearance under the country’s relevant laws was a mandatory step. Although it was initially expected that the approval process—including document reviews and regulatory assessments—would take considerable time, our close communication with stakeholders and the anticipated positive impact of the acquisition led to an early approval. This also demonstrates that the acquisition has been recognized as reasonable and necessary from a policy perspective.

With the Irish merger clearance secured, only the U.S. business combination approval remains. Based on the progress to date, we do not foresee any significant issues, and the company will continue to prepare thoroughly and prudently to ensure that the remaining approval is granted as soon as possible.

Upon completion of the acquisition, Celltrion expects to strengthen its competitiveness through:

• Mitigation of tariff-related risks,

• Management of geopolitical risks by diversifying manufacturing sites, and

• Establishment of an integrated value chain covering production, packaging, logistics, and sales within the United States.

In addition, the acquisition is expected to generate immediate CMO revenue, enabling the early recovery of our investment. This transaction will serve as an important milestone in expanding our global business capabilities and will ultimately contribute to enhancing shareholder value.

Celltrion will continue to provide timely updates on future developments to maintain the trust and support of our valued shareholders.

Thank you.